Anti-Human PCSK9 Recombinant Antibody (Bococizumab) (CAT#: TAB-H10)

Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Neut

Figure 1 Effect of Antidrug Antibodies on the Durability of Low-Density Lipoprotein (LDL) Cholesterol Lowering and on Plasma Bococizumab and PCSK9 Levels.

Figure 1 Effect of Antidrug Antibodies on the Durability of Low-Density Lipoprotein (LDL) Cholesterol Lowering and on Plasma Bococizumab and PCSK9 Levels.

Panel A shows the effect of generalized antidrug antibodies (ADAs) on LDL cholesterol levels among the patients who received placebo and among those who received bococizumab, according to whether the patients were ADA-negative throughout the trial, had ADA titers in the lowest two thirds of maximum titers (<1:1176) during follow-up, had ADA titers in the highest third of titers (≥1:1176) during follow-up, or were in the subgroup with ADA titers in the top 10% (≥1:5674). The light blue bars indicate prevalent rates of antibodies at each time point, and the dark blue bars the cumulative incidence of antibody positivity during follow-up. Panel B shows plasma bococizumab levels and Panel C total plasma proprotein convertase subtilisin–kexin type 9 (PCSK9) levels over time, according to the ADA titer. Panel D shows the effect of the neutralizing antibody (NAb) titer on LDL cholesterol levels.

Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.

Neut

Figure 2 Variability in the Reduction in LDL Cholesterol Levels, According to the Presence or Absence of Antidrug Antibodies (ADAs).

Figure 2 Variability in the Reduction in LDL Cholesterol Levels, According to the Presence or Absence of Antidrug Antibodies (ADAs).

Waterfall plots for individual patients who received bococizumab show the percent change from baseline in LDL cholesterol levels at 12 weeks (Panel A) and at 52 weeks among the patients in whom antidrug antibodies developed (Panel B) and among those in whom antidrug antibodies did not develop (Panel C). Data are limited to the patients who reported having received bococizumab in the 21 days before the measurement of LDL cholesterol.

Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.


Specifications

  • Host Species
  • Human
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG2 - kappa
  • Specificity
  • PCSK9(proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proproteine convertase 9, PC9) [Homo sapiens]
  • Species Reactivity
  • Human
  • Applications
  • WB, FC, IP, ELISA, Neut, FuncS, IF
  • CAS
  • 1407495-02-6
  • Generic Name
  • bococizumab
  • ChEMBL
  • CHEMBL3137349
  • MW
  • 145.1 kDa
  • Related Disease
  • Hypercholesterolemia

Product Property

  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.

Applications

  • Application Notes
  • The PCSK9 antibody has been reported in applications of WB, FC, IP, ELISA, Neut, FuncS, IF.

Target

  • Alternative Names
  • bococizumab;1407495-02-6;PF-04950615;RN316;RN-316;L1L3;PCSK9;proprotein convertase subtilisin/kexin type 9;HCHOLA3, hypercholesterolemia, autosomal dominant 3;FH3;NARC 1;NARC1;NARC-1;HCHOLA3;

Related Resources

  • Biosimilar Overview
Please refer to Bococizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Bococizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Bococizumab"

Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol

See other products for "PCSK9"

Single-domain Antibody

CAT Product Name Application Type
TAB-0080CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKE2) FuncS, Inhib, FC, WB Single domain antibody
TAB-0081CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKF8) FuncS, Inhib, FC, WB Single domain antibody
TAB-0082CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKG1) FuncS, Inhib, FC, WB Single domain antibody
TAB-0083CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (P1.70) FuncS, Inhib, FC, WB Single domain antibody
TAB-0084CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKE1) FuncS, Inhib, FC, WB Single domain antibody

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1826CQ Recombinant Human Anti-PCSK9 Antibody, Unconjugated Neut IgG1

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-758 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Lodelcizumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-H10 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS ADCC enhanced antibody
AFC-TAB-H59 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Ralpancizumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-H31 Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF Human IgG1, λ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H10. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare